SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-021078
Filing Date
2024-05-23
Accepted
2024-05-23 06:02:41
Documents
20
Period of Report
2024-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 59539
2 ex4-1.htm EX-4.1 121210
3 ex5-1.htm EX-5.1 24167
4 ex10-1.htm EX-10.1 276592
5 ex10-2.htm EX-10.2 117467
6 ex99-1.htm EX-99.1 14469
7 ex99-1_001.jpg GRAPHIC 2197
8 ex5-1_001.jpg GRAPHIC 16260
  Complete submission text file 0001493152-24-021078.txt   942459

Data Files

Seq Description Document Type Size
9 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gtbp-20240521.xsd EX-101.SCH 3024
10 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gtbp-20240521_lab.xml EX-101.LAB 34240
11 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gtbp-20240521_pre.xml EX-101.PRE 22365
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3680
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 24975106
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)